Success Metrics

Clinical Success Rate
90.3%

Based on 204 completed trials

Completion Rate
90%(204/226)
Active Trials
18(6%)
Results Posted
35%(72 trials)
Terminated
22(8%)

Phase Distribution

Ph phase_1
22
8%
Ph phase_3
79
28%
Ph phase_4
90
32%
Ph phase_2
45
16%
Ph not_applicable
34
12%
Ph early_phase_1
2
1%

Phase Distribution

24

Early Stage

45

Mid Stage

169

Late Stage

Phase Distribution272 total trials
Early Phase 1First-in-human
2(0.7%)
Phase 1Safety & dosage
22(8.1%)
Phase 2Efficacy & side effects
45(16.5%)
Phase 3Large-scale testing
79(29.0%)
Phase 4Post-market surveillance
90(33.1%)
N/ANon-phased studies
34(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.4%

204 of 236 finished

Non-Completion Rate

13.6%

32 ended early

Currently Active

18

trials recruiting

Total Trials

282

all time

Status Distribution
Active(23)
Completed(204)
Terminated(32)
Other(23)

Detailed Status

Completed204
Terminated22
unknown22
Recruiting16
Withdrawn10
Not yet recruiting4

Development Timeline

Analytics

Development Status

Total Trials
282
Active
18
Success Rate
90.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (0.7%)
Phase 122 (8.1%)
Phase 245 (16.5%)
Phase 379 (29.0%)
Phase 490 (33.1%)
N/A34 (12.5%)

Trials by Status

enrolling_by_invitation10%
not_yet_recruiting41%
recruiting166%
active_not_recruiting21%
terminated228%
completed20472%
unknown228%
withdrawn104%
suspended10%

Recent Activity

Clinical Trials (282)

Showing 20 of 282 trialsScroll for more
NCT04939090Phase 3

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Active Not Recruiting
NCT04478838Phase 4

"Extended" (Alternate Day) Antipsychotic Dosing

Recruiting
NCT06331520Phase 3

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Completed
NCT07482891Phase 4

An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC

Not Yet Recruiting
NCT07208305Phase 3

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

Recruiting
NCT07442890Not Applicable

A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron

Not Yet Recruiting
NCT05303064Phase 3

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Recruiting
NCT07413809Phase 3

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

Recruiting
NCT06995508Phase 2

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

Recruiting
NCT06200181Phase 3

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

Recruiting
NCT00183625Phase 4

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

Completed
NCT05669742Phase 3

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Recruiting
NCT05814640Phase 1

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

Recruiting
NCT04216329Phase 1

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Active Not Recruiting
NCT05705492Phase 2

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Recruiting
NCT05676294Phase 2

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

Completed
NCT07263191

A Study of Olanzapine in Participants With Bipolar Disorder.

Recruiting
NCT03118986Phase 2

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Recruiting
NCT03367572Phase 3

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Completed
NCT06175273Phase 2

Pediatric Oncology Nutrition Intervention Trial

Completed

Drug Details

Intervention Type
DRUG
Total Trials
282